EcoDrugPlus

Histone Deacetylase 8

Ensembl ID : ENSACLG00000018919
Gene Symbol: HDAC8
3 Cross references
206 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 1

Ensembl ID : ENSACLG00000023705
Gene Symbol: HCAR1
2 Cross references
233 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSACLG00000015862
Gene Symbol: HCN4
3 Cross references
219 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSACLG00000007139
Gene Symbol: HCN4
1 Cross references
210 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSACLG00000003616
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Ileal Sodium/bile Acid Cotransporter-Like

Ensembl ID : ENSACLG00000022706
Gene Symbol: LOC113007920
4 Cross references
204 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSACLG00000010789
Gene Symbol: IKBKB
3 Cross references
198 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSACLG00000018654
Gene Symbol: IMPDH2
4 Cross references
202 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1a

Ensembl ID : ENSACLG00000025116
Gene Symbol: LOC113026882
4 Cross references
259 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSACLG00000022668
Gene Symbol: LOC113008706
4 Cross references
258 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSACLG00000024736
Gene Symbol: INPP5D
3 Cross references
216 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSACLG00000021919
Gene Symbol: IGF1R
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).